

Most Read This Week
- Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitor Therapy for mRCC
- Efficacy of Cabozantinib as Second-Line Therapy Based on Type of First-Line Therapy Received
- Role of Stereotactic Ablative Body Radiotherapy in RCC
- Association of Weight Loss With Cabozantinib Use in Patients With mRCC
- Validity of Routine cfDNA Panel Testing in Patients With ccRCC
Recently Updated
- Impact of Trial Eligibility on Use of ICI-Based Combination Therapy in Patients With Metastatic RCC
- Association of Weight Loss With Cabozantinib Use in Patients With mRCC
- Efficacy of Cabozantinib as Second-Line Therapy Based on Type of First-Line Therapy Received
- Validity of Routine cfDNA Panel Testing in Patients With ccRCC
- Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitor Therapy for mRCC